Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank90
3Y CAGR+48.8%
5Y CAGR-14.4%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+48.8%/yr
vs +54.9%/yr prior
5Y CAGR
-14.4%/yr
Recent acceleration
Acceleration
-6.1pp
Decelerating
Percentile
P90
Near historical high
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 41.79% |
| Q3 2025 | -33.74% |
| Q2 2025 | 73.99% |
| Q1 2025 | -14.56% |
| Q4 2024 | -515.72% |
| Q3 2024 | 62.63% |
| Q2 2024 | 64.11% |
| Q1 2024 | 41.05% |
| Q4 2023 | 2.28% |
| Q3 2023 | 3.13% |
| Q2 2023 | -37.26% |
| Q1 2023 | 31.78% |
| Q4 2022 | 12.69% |
| Q3 2022 | 0.30% |
| Q2 2022 | 24.96% |
| Q1 2022 | -137.20% |
| Q4 2021 | 41.54% |
| Q3 2021 | 1.26% |
| Q2 2021 | 6.27% |
| Q1 2021 | -1338.15% |
| Q4 2020 | 91.17% |
| Q3 2020 | 8.94% |
| Q2 2020 | 14.13% |
| Q1 2020 | -11.36% |
| Q4 2019 | -14.48% |
| Q3 2019 | 3.06% |
| Q2 2019 | 22.07% |
| Q1 2019 | -15.28% |
| Q4 2018 | -17.10% |
| Q3 2018 | -12.19% |
| Q2 2018 | 14.18% |
| Q1 2018 | -57.73% |
| Q4 2017 | -31.08% |
| Q3 2017 | -12.75% |
| Q2 2017 | -0.84% |
| Q1 2017 | -4.88% |
| Q4 2016 | -38.77% |
| Q3 2016 | -38.42% |
| Q2 2016 | 13.79% |
| Q1 2016 | -14.74% |